Aardvark Therapeutics, Inc. (AARD) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aardvark Therapeutics, Inc. (AARD:NASDAQ), powered by AI.

Current Price
$3.72
P/E Ratio
-1.3
Market Cap
73M
Sector
Healthcare
What is the Aardvark Therapeutics, Inc. stock price forecast?

Aardvark Therapeutics, Inc. is currently trading at $3.72. View real-time AI analysis on Alpha Lenz.

What is Aardvark Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Aardvark Therapeutics, Inc. on Alpha Lenz.

What is Aardvark Therapeutics, Inc.'s P/E ratio?

Aardvark Therapeutics, Inc.'s P/E ratio is -1.3.

Aardvark Therapeutics, Inc.

NASDAQ · AARD
$3.72-0.12(-3.12%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Aardvark Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Aardvark Therapeutics, Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -221.5%.

Ask for details

Company Overview

Aardvark Therapeutics Inc. operates within the dynamic healthcare industry, focusing on the development and commercialization of innovative therapeutics. The primary goal of Aardvark Therapeutics is to address significant unmet needs in medical treatments, advancing the landscape of healthcare through scientific discovery and technological advancement. With a strong emphasis on research and development, the company is engaged in creating a pipeline of products that offer novel approaches to treating various health conditions. These efforts can have far-reaching impacts across multiple sectors within the industry, including biopharmaceuticals and biotechnology. Aardvark Therapeutics Inc. plays a critical role in the market by driving forward the possibilities of next-generation therapies, contributing to both patient outcomes and healthcare system advancements. As the company seeks to bring transformative solutions to market, its activities are closely monitored by stakeholders interested in the progression of medical science and its applicability to everyday health challenges.

CEODr. Tien-Li Lee M.D.
SectorHealthcare
IndustryBiotechnology
Employees31

Company Statistics

FY 2025

Profile

$73.00MMarket Cap
$0.00Revenue
0.00Shares Out
31Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.27P/E
0.68P/B
N/AEV/Sales
-0.42EV/EBITDA
-1.35P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-59.16%ROA
-221.55%ROE
-64.44%ROIC

Financial Health

$47.05MCash & Cash Equivalents
$-36.50MNet Debt
9.89%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Aardvark Therapeutics, Inc. (ticker: AARD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 31 employees. Market cap is $73M.

The current price is $3.72 with a P/E ratio of -1.27x and P/B of 0.68x.

ROE is -221.55%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Aardvark Therapeutics, Inc. (AARD) Stock Forecast 2026 $3.72 — Price, Financials & Analyst Targets | Alpha Lenz